Association of British Clinical Diabetologists

Live ABCD nationwide audits

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above - dapagliflozin selectively inhibits SGLT2 in the renal proximal tubule leading to increased urinary excretion of excess glucose. In clinical trials this translated into reduction in HbA1c and weight - click to enlarge

 
 

Above: At 30 weeks exenatide QW significantly improved HbA1c reductions compared to twice daily exenatide - click to enlarge

 
 

Above: In clinical trials there was considerably less intra-subject variability with degludec than with glargine. Potentially therefore patients with very variable patterns of home blood glucose monitoring may benefit from a switch to degludec - click to enlarge

 
 

Above: In both the ABCD nationwide exenatide and liraglutide audits, it was found that whilst about 60% patients achieved improvement in both HbA1c and weight, less than half of these achieved this to the criteria levels set by NICE. Many patients achieved considerable HbA1c reduction but not much weight reduction, whilst many others achieved considerable weight reduction but not much HBA1c reductions - click to enlarge

 
 
Above - in clinical trials, body weight increased with insulin glargine used in a treat to target algorithm, whereas with IDegLira body weight decreased and the fall in HbA1c was considerably more. The audit may give insight into whether these advantages translate into real clinical practice - click to enlarge

Current, live, ABCD nationwide audits of new therapies in real clinical practice

ABCD has learned from its previous nationwide audits. It has learned the best ways of undertaking successful nationwide audits. It has also realised how much clinically useful information can be obtained from the audit information to improve patient care. This applied in particular to the ABCD nationwide GLP1-RA audits of exenatide and liraglutide. Similarly now we are gaining considerable insight into the SGLT2 class. Many of our national audits are now on N3 which is the latest version of NHSnet. The audits currently being undertaken are:

Nationwide audits of new diabetes therapies on N3

Nationwide FreeStyle Libre audit
The nationwide audit of the the FreeStyle Libre (FSL) glucose monitoring system represents our first audit of a device. All using FSL
in adults and paediatric patients with either  type 1 or  type 2 diabetes are invited to join the audit. The tool for the audit is currently being developed and should be available soon. In the meantime paper forms are available (click here to be sent the forms) fso that you can start collecting data without delay in readiness for when the on-line tool becomes available. Click here for more information and to join the audit.

Nationwide empagliflozin audit
The nationwide audit of the SGLT2 inhibitor, empaglflozin (Jardiance®) launched in March 2017. All users of empagliflozin are invited to join the audit. The tool provided for on-line data entry has a facility for easy, sophisticated, analysis of the data entered by the local centre entering the data. At the same time the data entered automatically becomes available, in anonymised form, for the national audit. Click here for more information and to join the audit.

Nationwide canagliflozin audit
The nationwide audit of the SGLT2 inhibitor, canaglflozin (Invocana®) launched in January 2016. All users of canaglifozin are invited to join the audit. The tool provided for on-line data entry has a facility for easy, sophisticated, analysis of the data entered by the local centre entering the data. At the same time the data entered automatically becomes available, in anonymised form, for the national audit. Click here for more information and to join the audit.

Nationwide dapagliflozin audit
The nationwide audit of the firs SGLT2 inhibitor available in the UK, dapaglflozin (Forxiga®) launched in October 2014. All users of dapagliflozin are invited to join the audit. The tool provided for on-line data entry has a facility for easy, sophisticated, analysis of the data entered by the local centre entering the data. At the same time the data entered automatically becomes available, in anonymised form, for the national audit. Click here for more information and to join the audit.

Nationwide exenatide QW audit
The nationwide audit of the once weekly GLP1 receptor agonist, exenatide QW (Bydureon®) audit launched in April 2014. All users of exenatide QW are invited to join the audit. The tool provided for on-line data entry has a facility for easy, sophisticated, analysis of the data entered by the local centre entering the data. At the same time the data entered automatically becomes available, in anonymised form, for the national audit. Click here for more information and to join the audit.

Other Nationwide audits of new diabetes therapies
The evolution of the ABCD audits started with a simple home-grown on-line audit tool for the exenatide audit which evolved into a new tool for the liraglutide audit which went through 3 iterations to end, in November 2014, with a secure on-line tool with sophisticated analysis capability to match the N3 tools mentioned above. The tool for the nationwide insulin degludec and IDegLira audits were developed from the lirgalutide audit tool so those who took part in that audit will find it particularly easy.

Nationwide IDegLira audit
The nationwide audit of IDegLira (Xultophy®), the fixed combination of insulin degludec and liraglutide in a single injection, launched in May 2017, at the Spring ABCD meeting in Belfast. All users of IDegLira are invited to join the audit. The tool provided for on-line data entry has a facility for easy, sophisticated, analysis of the data entered by the local centre entering the data. At the same time the data entered, automatically becomes available, in anonymised form, for the national audit. Click here for more information and to join the audit.

Nationwide degludec audit
The nationwide audit of the new ultra-long acting insulin analogue, degludec (Tresiba®) launched in November 2014, at the Autumn ABCD meeting at the Royal College of Physicians. All users of degludec are invited to join the audit. The tool provided for on-line data entry has a facility for easy, sophisticated, analysis of the data entered by the local centre entering the data. At the same time the data entered, automatically becomes available, in anonymised form, for the national audit. Click here for more information and to join the audit.

   Main ABCD homepage

ABCD canagliflozin audit

ABCD dapagliflozin audit

ABCD empagliflozin audit

ABCD FreeStyle Libre audit

 ABCD exenatide QW audit

ABCD semaglutide audit

ABCD IDegLira audit

ABCD degludec audit

ABCD liraglutide audit

ABCD exenatide audit

ABCD worldwide audits

Endobarrier worldwide registry

Contact us

     

Working to support high quality diabetes care in the UK